X

Trial Profile

A Single-Ascending and Repeat-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3561774

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solbinsiran (Primary)
Indications Cardiovascular disorders; Metabolic disorders
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

08 Apr 2024 Results presented at the 73rd Annual Scientific Session of the American College of Cardiology.
09 Aug 2022 Status changed from active, no longer recruiting to completed.
16 Dec 2021 Planned End Date changed from 28 Apr 2022 to 17 May 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com